A light exposure tracker designed to improve the circadian entrainment for Alzheimer Disease patients

一种光暴露跟踪器，旨在改善阿尔茨海默病患者的昼夜节律变化

• 批准号: 10707191
• 负责人: Erik Page
• 金额: $ 122.97万
• 依托单位: BLUE IRIS LABS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707191
• 关键词: Address; Aging; Agitation; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Area; Assessment tool; Automation; Caregivers; Cellular Phone; Characteristics; Circadian Dysregulation; Circadian Rhythms; Clinical Trials; Cognition; Companions; Controlled Environment; Darkness; Data; Data Collection; Data Storage and Retrieval; Dementia; Development; Devices; Disease; Elderly; Exposure to; Eye; Family; Feedback; Future; Goals; Health; Home; Human; Individual; Industry; Infrastructure; Internet; Intervention; Knowledge; Laboratories; Laboratory Study; Life; Light; Lighting; Maps; Measurement; Measures; Melatonin; Monitor; Moods; Neural Pathways; Neurosecretory Systems; Patients; Pattern; Personal Satisfaction; Persons; Phase; Phototherapy; Population; Process; Recommendation; Recording of previous events; Research; Research Personnel; Retinal Photoreceptors; Risk Reduction; Scientist; Sleep; Sleep Disorders; Small Business Innovation Research Grant; System; Technology; Testing; United States National Institutes of Health; Visualization; Wakefulness; Work; alertness; circadian; circadian pacemaker; cognitive testing; cohort; commercialization; cost effective; dashboard; design; digital; effectiveness testing; experience; exposed human population; field study; improved; improvement on sleep; interest; light intensity; mild cognitive impairment; negative affect; novel; response; sleep quality; success; tool; wireless

Project Summary The NIH has recognized the importance of circadian rhythms and sleep in Alzheimer’s disease (AD) and related dementias (ADRD) progression, recently releasing a Notice of Special Interest titled “Sleep Disorders and Circadian Clock Disruption in Alzheimer’s Disease and other Dementias of Aging.” The NIH has also noted that improving sleep quality is among the few interventions that people can take to reduce the risk of developing AD/ADRD later in life. Light therapy has shown great promise as a non-pharmacological treatment in helping to regulate sleep and in improving cognition in older adults with AD/ADRD. Perhaps not surprisingly given our evolutionary history, studies in this area can be simply summarized as: bright days and dark nights are beneficial for human health generally and AD/ADRD health specifically. Studies have demonstrated that daytime light exposure can consolidate and increase nighttime sleep efficiency, while also increasing daytime wakefulness and reducing evening agitation in AD/ADRD patients. But critical knowledge gaps exist, including information on the light exposure humans typically experience—at both individual and population levels—and how these vary from optimal light exposure patterns. Also missing are tools to collect these data and tools for individuals, researchers, and caregivers to monitor and control light exposure. In order to address these gaps, researchers have developed a novel, cost-effective, battery-powered light spectrometer which can measure circadian light characteristics and be discreetly mounted to walls or used as a wearable. This networked device provides continuous, remote data collection and storage, allowing interested parties to easily monitor circadian lighting conditions and adjust their lighting as needed. This project would build on these researcher-oriented tools and technologies to commercialize a new consumer- oriented version of this light exposure tracking system targeting patients with mild cognitive impairment (MCI) or early stage Alzheimer’s disease still living at home. Light exposure data collected by these systems would be used to provide actional recommendations and/or automations to improve circadian entrainment and overall health of AD/ADRD patients. The work proposed here will focus on the development of a new light exposure tracker, companion apps, and dashboards that gather much of the same detailed lighting data as the researcher- oriented device, but present these data in ways that are understandable and helpful for people with AD/ADRD and their caregivers. Integrations with related connected products, such as sleep trackers and smart lamps, will also be investigated. A clinical trial is proposed that includes both MCI and AD/ADRD patients living at home. The trial will characterize the light exposure that these cohorts experience and test a variety of interventions intended to bring their light exposure patterns more in line with patterns known to support circadian health.

项目摘要 NIH认识到昼夜节律和Slezheimer病（AD）和相关的重要性 痴呆症（ADRD）的进展，最近发布，题为“睡眠障碍和安德斯和 《阿尔茨海默氏病》和其他衰老痴呆症中的昼夜节律破坏。 在很少有少数人可以承受发展的风险中，改善睡眠质量是 较晚的广告/adrd。 在AD/ADRD的老年人中调节睡眠和预见。 进化历史，该领域的研究可以总结为：明亮的日子和黑暗的夜晚是有益的 针对人类健康和广告/ADRD健康。 曝光罐可以罐装罐可以可以折磨夜间睡眠效率，同时也增加了白天的Wakeefrness和 减少AD/ADRD患者的事件。 轻曝光人类通常在个人和人口水平上经历 从最佳的光线曝光模式中也缺少 研究人员和护理人员监视和控制这些差距。 已经开发了一种新颖的，成本效益的电池供电的光谱仪 特征并被隔离到墙壁上或用作可穿戴设备 连续的，远程数据收集和存储 条件并根据需要调整照明。 该项目将以这些面向研究人员的工具和技术为基础，以使新的消费者商业化 - 这种轻曝光跟踪系统的定向版本针对患者患者患有轻度认知障碍（MCI） 或阿尔茨海默氏病早期仍住在家里。 用于提供活动推荐和/或自动化，以改善循环和整体 AD/ADRD患者的健康。 跟踪器，伴侣应用程序和仪表板收集与研究人员相同的详细照明数据 定向设备，但以AD/AD/ADRD可以理解和帮助的方式呈现数据 及其护理人员与相关连接的产品（例如睡眠跟踪器和智能灯）集成 也可以调查。 该试验将表征曝光的光曝光，该体验经验测试了多种多样的侵略性 旨在使光线曝光模式更加一致，以支持支持昼夜节律的模式。